Skip to main content

Advertisement

Table 3 Association between atopy and incidence of respiratory symptoms stratified by the treatment group and gender

From: Atopy is a risk factor for respiratory symptoms in COPD patients: results from the EUROSCOP study

Respiratory symptom Total population Males Females
  OR (95% CI) of atopy OR (95% CI) of atopy OR (95% CI) of atopy
  Placebo Budesonide Placebo Budesonide Placebo Budesonide
Wheezing at any time 1.15 (0.71–1.87) 0.79 (0.45–1.43) 1.24 (0.74–2.08) 0.92 (0.48–1.75) 0.64 (0.15–2.78) 0.43 (0.10–1.85)
Cough day/night or a.m. 1.79 (1.03–3.08) * 0.83 (0.42–1.62) 1.69 (0.93–3.08)# 0.84 (0.38–1.84) 2.52 (0.64–9.86) 0.60 (0.17–2.08)
Phlegm day/night or a.m. 1.50 (0.84–2.69) 0.91 (0.54–1.53) 1.55 (0.82–2.93) 0.85 (0.46–1.59) 1.30 (0.36–4.67) 0.92 (0.38–2.27)
Trouble with breathing 1.12 (0.66–1.89) 0.68 (0.37–1.24) 1.09 (0.59–1.99) 0.79 (0.42–1.51) 1.23 (0.44–3.44) 0.22 (0.4–1.13)#
Woken with chest tightness 1.33 (0.74–2.38) 1.07 (0.57–1.99) 1.35 (0.69–2.65) 1.08 (0.55–2.12) 1.08 (0.27–4.34) 1.11 (0.23–5.39)
Attack of dyspnea after activity 0.98 (0.59–1.62) 1.49 (0.88–2.51) 0.76 (0.43–1.33) 1.55 (0.88–2.73)$ 2.79 (0.94–8.31)# 0.89 (0.22–3.62)
  1. *OR is significant at p < 0.05. Each model was adjusted for sex, age, BMI, pack years of smoking, number of cigarettes and FEV1 % pred.
  2. #Trend (0.05 < p. value < 0.1).
  3. $Interaction between Phadiatop and treatment group has a p.value < 0.05.